tiprankstipranks
Trending News
More News >
Akso Health Group Sponsored ADR (AHG)
:AHG

Akso Health Group Sponsored ADR (AHG) AI Stock Analysis

Compare
151 Followers

Top Page

AH

Akso Health Group Sponsored ADR

(NASDAQ:AHG)

Rating:45Neutral
Price Target:
The overall stock score for Akso Health Group is low due to significant challenges in profitability and revenue stability. The technical analysis points to negative momentum, while the valuation is weak with a negative P/E ratio. The recent market reaction post-earnings call was negative, further impacting the score. Without positive corporate events or earnings call highlights, the outlook remains cautious.

Akso Health Group Sponsored ADR (AHG) vs. SPDR S&P 500 ETF (SPY)

Akso Health Group Sponsored ADR Business Overview & Revenue Model

Company DescriptionAkso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, etc. It also offers consultancy and information technology support services; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Beijing, China. As of July 13, 2021, Akso Health Group operates as a subsidiary of Webao Limited.
How the Company Makes MoneyAkso Health Group generates revenue through a diversified model that includes providing healthcare services such as traditional Chinese medicine consultations, wellness management programs, and integrated healthcare solutions. The company collaborates with healthcare institutions and leverages its expertise in both traditional and modern medical practices to offer a wide range of services. Revenue streams are primarily driven by patient consultations, treatment programs, and strategic partnerships with healthcare providers and technology firms that enhance its service offerings. Key factors contributing to its earnings include the growing demand for alternative medicine, expansion into new markets, and the integration of technology in healthcare services to improve efficiency and patient outcomes.

Akso Health Group Sponsored ADR Financial Statement Overview

Summary
Akso Health Group faces challenges with profitability and revenue stability. While its balance sheet shows a strong equity position, the lack of comprehensive debt information introduces uncertainty in financial leverage assessment. Cash flow has improved recently, but historical volatility poses a risk. Overall, the company needs to address its revenue and profitability issues to enhance financial health.
Income Statement
40
Negative
The company has experienced significant revenue volatility, with a steep decline in recent years. The net profit margin is severely negative due to substantial net losses, indicating poor profitability. There is no gross profit data to assess cost efficiency, and EBIT/EBITDA margins are unavailable for additional insights.
Balance Sheet
55
Neutral
The equity ratio is strong, indicating a solid equity base relative to total assets. However, the lack of debt data prevents a full assessment of leverage. Stockholders' equity has increased recently, but the company has a history of equity fluctuations.
Cash Flow
50
Neutral
The company has shown inconsistent operating cash flows, with recent positive figures. Free cash flow has been volatile, with significant growth over the past year, albeit from a low base. The cash flow to net income ratio is unreliable due to negative net income.
BreakdownMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue2.41M13.18M6.00M1.75M6.91M
Gross Profit122.13K1.27M605.13K1.21M6.91M
EBITDA0.00-14.25M-2.44M-2.07M-16.30M
Net Income-9.46M-13.08M-16.85M-31.55M-71.20M
Balance Sheet
Total Assets142.02M20.46M50.68M31.69M78.38M
Cash, Cash Equivalents and Short-Term Investments85.17M7.92M21.93M15.13M10.93M
Total Debt2.00M9.69M37.20M10.00M20.79M
Total Liabilities3.59M11.62M38.39M14.41M30.28M
Stockholders Equity138.37M8.73M12.28M17.27M48.10M
Cash Flow
Free Cash Flow1.35M-3.25M-8.63M10.06M-56.18M
Operating Cash Flow1.35M-3.25M-8.63M10.06M-55.87M
Investing Cash Flow-54.72M18.47M-19.96M-662.0012.78M
Financing Cash Flow131.65M-27.51M34.78M-9.04M-3.97M

Akso Health Group Sponsored ADR Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.12
Price Trends
50DMA
1.43
Negative
100DMA
1.32
Negative
200DMA
1.21
Negative
Market Momentum
MACD
-0.07
Positive
RSI
35.23
Neutral
STOCH
13.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHG, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.43, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 35.23 is Neutral, neither overbought nor oversold. The STOCH value of 13.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AHG.

Akso Health Group Sponsored ADR Risk Analysis

Akso Health Group Sponsored ADR disclosed 55 risk factors in its most recent earnings report. Akso Health Group Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations. Q1, 2023

Akso Health Group Sponsored ADR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$227.49M6.1210.39%4.90%13.93%-23.70%
YRYRD
73
Outperform
$531.40M2.8814.69%3.58%12.45%-36.64%
QDQD
65
Neutral
$497.03M12.622.77%0.54%
63
Neutral
CHF22.87B15.2710.81%2.12%47.85%-11.82%
FOFOA
62
Neutral
$258.90M4.0921.28%4215.36%
61
Neutral
$295.69M-11.37%-5.79%59.24%
AHAHG
45
Neutral
$268.69M-6.43%-81.66%-214.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AHG
Akso Health Group Sponsored ADR
1.12
-0.02
-1.75%
MFIN
Medallion Financial
9.79
2.52
34.66%
YRD
Yiren Digital
6.15
1.88
44.03%
QD
Qudian
3.01
1.14
60.96%
FOA
Finance of America Companies
23.59
18.79
391.46%
OPRT
Oportun Financial
6.87
4.33
170.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 13, 2024